Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study

2018/12/15 by Ralf Reilmann, Andrew McGarry, Igor D. Grachev +146 · 1 citation
Medicine · Neuroscience · #Amyotrophic Lateral Sclerosis Research #Genetic Neurodegenerative Diseases #Neurological disorders and treatments

paper · doi:10.1016/s1474-4422(18)30391-0

openalex publication_date 2018/12/15 · crossref created 2018/12/15 · crossref issued 2019/02/01 · crossref published 2019/02/01 · crossref published-print 2019/02/01 · openalex created_date 2025/10/10 · crossref deposited 2025/10/26 · crossref indexed 2026/07/29 · openalex updated_date 2026/07/30

Citations

• The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly Persons
• Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data
• The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults
• Huntington's disease
• Pridopidine activates neuroprotective pathways impaired in Huntington Disease
• The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease
• Unified Huntington's disease rating scale: Reliability and consistency
• A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease

Cited by

• Bernhard Landwehrmeyer [wikipedia]